NASDAQ · SABS
SAB Biotherapeutics, Inc.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
Loading market information…
NASDAQ · EVAX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evaxion Biotech A/S’s quoted price sits in the lower half of its reported 52-week range, 55.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Evaxion Biotech A/S’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evaxion Biotech A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 27, 2025 | -$0.29+55.38% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | -$3.40-1,207.69% vs estimate | $122.00K-92.65% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | -$0.20+35.48% vs estimate | $3.02M+2,346.22% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
$1.02$0.00 (0.0%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.45% below the high.
$2.23-$0.04 (-1.76%)
Veru Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.58% below the high.
$5.34$0.00 (0.0%)
Generation Bio Co.’s quoted price sits in the upper half of its reported 52-week range, 28.95% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$0.39-$0.03 (-6.02%)
Reviva Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.47% below the high.
